GlassScriptPhysician profile
Sherwin Desouza
NPI 1487035242
$14,989.27
in general payments reported to CMS, 2019-2025
26 companies · $7,494 in 2025
The $7,494 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $720 · 2021: $75.42 · 2022: $393 · 2023: $392 · 2024: $5,914 · 2025: $7,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,071 · Consulting Fee: $4,000 · Food and Beverage: $1,870 · Travel and Lodging: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,070.83 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $1,870.16 |
| Travel and Lodging | $859.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,079.20 | 2021-2025 | |
| Novo Nordisk INC | $739.71 | 2020-2025 | Alhemo |
| Incyte Corporation | $150.40 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $84.21 | 2024-2025 | Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $80.78 | 2024 | |
| Genmab U.S., INC. | $79.98 | 2021-2024 | Tivdak |
| Amgen INC. | $79.15 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Eisai INC. | $76.28 | 2022-2024 | |
| Genentech USA, INC. | $62.40 | 2022-2025 | Tecentriq, Alecensa |
| Takeda Pharmaceuticals U.S.A., INC. | $61.66 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $60.96 | 2021-2023 | Ultomiris |
| Pfizer INC. | $56.43 | 2024 | |
| Blueprint Medicines Corporation | $54.12 | 2022-2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $41.63 | 2023-2025 | Keytruda |
| Jazz Pharmaceuticals INC. | $38.13 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $36.66 | 2024 | Pyrukynd |
| Astellas Pharma US INC | $33.57 | 2023 | Xospata |
| Beigene USA, INC. | $33.29 | 2021-2023 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.59 | 2022 | |
| Glaxosmithkline, LLC. | $19.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.77 | 2022 | |
| Adc Therapeutics America, INC. | $18.50 | 2024 | |
| Seagen INC. | $17.99 | 2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $16.04 | 2022 | |
| Daiichi Sankyo INC. | $14.34 | 2024 | Enhertu |
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherwin Desouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.